Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
JAMA Dermatol. 2023 Oct 1;159(10):1085-1092. doi: 10.1001/jamadermatol.2023.2875.
Data on the association between atopic dermatitis (AD) and inflammatory bowel disease (IBD) are inconsistent. Few studies have examined the association of AD or AD severity with risk of ulcerative colitis (UC) and Crohn disease (CD) separately.
To examine the risk of new-onset IBD, UC, and CD in children and adults with AD.
DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study assessed patients with AD matched with up to 5 controls on age, practice, and index date. Treatment exposure was used as a proxy for AD severity. Data were retrieved from The Health Improvement Network, a UK electronic medical record database, for January 1, 1994, to February 28, 2015. Data analysis was performed from January 8, 2020, to June 30, 2023.
Outcomes of interest were incident IBD, UC, and CD. Logistic regression was used to examine the risk for each outcome in children and adults with AD compared with controls.
A total of 1 809 029 pediatric controls were matched to 409 431 children with AD (93.2% mild, 5.5% moderate, and 1.3% severe). The pediatric cohort ranged in median age from 4 to 5 years (overall range, 1-10 years), was predominantly male (936 750 [51.8%] controls, 196 996 [51.6%] with mild AD, 11 379 [50.7%] with moderate AD, and 2985 [56.1%] with severe AD), and with similar socioeconomic status. A total of 2 678 888 adult controls were matched to 625 083 adults with AD (65.7% mild, 31.4% moderate, and 2.9% severe). The adult cohort ranged in median age from 45 to 50 years (overall range, 30-68 years) and was predominantly female (1 445 589 [54.0%] controls, 256 071 [62.3%] with mild AD, 109 404 [55.8%] with moderate AD, and 10 736 [59.3%] with severe AD). In fully adjusted models, children with AD had a 44% increased risk of IBD (hazard ratio [HR], 1.44; 95% CI, 1.31-1.58) and a 74% increased risk of CD (HR, 1.74; 95% CI, 1.54-1.97), which increased with worsening AD; however, they did not have increased risk of UC (HR, 1.09; 95% CI, 0.94-1.27) except for those with severe AD (HR, 1.65; 95% CI, 1.02-2.67). Adults with AD had a 34% (HR, 1.34; 95% CI, 1.27-1.40) increased risk of IBD, a 36% (HR, 1.36; 95% CI, 1.26-1.47) increased risk of CB, and a 32% (HR, 1.32; 95% CI, 1.24-1.41) increased risk of UC, with risk increasing with worsening AD.
In this cohort study, children and adults with AD had an increased risk of IBD, with risk varying by age, AD severity, and IBD subtype. These findings provide new insights into the association between AD and IBD. Clinicians should be aware of these risks, particularly when selecting systemic treatments for AD in patients who may have coincident gastrointestinal symptoms.
特应性皮炎(AD)与炎症性肠病(IBD)之间关联的数据不一致。很少有研究分别检查 AD 或 AD 严重程度与溃疡性结肠炎(UC)和克罗恩病(CD)风险之间的关系。
检查患有 AD 的儿童和成人新发 IBD、UC 和 CD 的风险。
设计、地点和参与者:这项基于人群的队列研究评估了 AD 患者,并与年龄、实践和指数日期相匹配的多达 5 名对照进行了匹配。治疗暴露被用作 AD 严重程度的替代指标。数据从 1994 年 1 月 1 日至 2015 年 2 月 28 日从英国电子病历数据库 Health Improvement Network 中检索。数据分析于 2020 年 1 月 8 日至 2023 年 6 月 30 日进行。
感兴趣的结果是新发 IBD、UC 和 CD。使用逻辑回归检查 AD 与对照相比,儿童和成人中每种结果的风险。
共匹配了 1809029 名儿科对照,其中 409431 名为儿童 AD(93.2%轻度、5.5%中度和 1.3%重度)。儿科队列的中位年龄从 4 岁到 5 岁(总体范围为 1 岁到 10 岁),主要为男性(936750[51.8%]对照,196996[51.6%]轻度 AD,11379[50.7%]中度 AD,2985[56.1%]重度 AD),且社会经济地位相似。共匹配了 2678888 名成年对照和 625083 名成年 AD(65.7%轻度、31.4%中度和 2.9%重度)。成年队列的中位年龄从 45 岁到 50 岁(总体范围为 30 岁到 68 岁),主要为女性(1445589[54.0%]对照,256071[62.3%]轻度 AD,109404[55.8%]中度 AD,10736[59.3%]重度 AD)。在完全调整的模型中,患有 AD 的儿童患 IBD 的风险增加 44%(风险比[HR],1.44;95%CI,1.31-1.58),患 CD 的风险增加 74%(HR,1.74;95%CI,1.54-1.97),这随着 AD 的恶化而增加;然而,除了患有严重 AD 的儿童(HR,1.65;95%CI,1.02-2.67)外,他们患 UC 的风险没有增加(HR,1.09;95%CI,0.94-1.27)。患有 AD 的成年人患 IBD 的风险增加 34%(HR,1.34;95%CI,1.27-1.40),患 CB 的风险增加 36%(HR,1.36;95%CI,1.26-1.47),患 UC 的风险增加 32%(HR,1.32;95%CI,1.24-1.41),随着 AD 的恶化,风险增加。
在这项队列研究中,患有 AD 的儿童和成人患 IBD 的风险增加,风险因年龄、AD 严重程度和 IBD 亚型而异。这些发现为 AD 和 IBD 之间的关联提供了新的见解。临床医生应意识到这些风险,特别是在为可能伴有胃肠道症状的患者选择 AD 的系统治疗时。